171 related articles for article (PubMed ID: 29731659)
1. Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation.
Asleh R; Briasoulis A; Berinstein EM; Wiener JB; Palla M; Kushwaha SS; Levy AP
Pharmgenomics Pers Med; 2018; 11():71-82. PubMed ID: 29731659
[TBL] [Abstract][Full Text] [Related]
2. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.
Blum S; Vardi M; Brown JB; Russell A; Milman U; Shapira C; Levy NS; Miller-Lotan R; Asleh R; Levy AP
Pharmacogenomics; 2010 May; 11(5):675-84. PubMed ID: 20415560
[TBL] [Abstract][Full Text] [Related]
3. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature.
Vardi M; Blum S; Levy AP
Eur J Intern Med; 2012 Oct; 23(7):628-32. PubMed ID: 22939808
[TBL] [Abstract][Full Text] [Related]
4. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial.
Milman U; Blum S; Shapira C; Aronson D; Miller-Lotan R; Anbinder Y; Alshiek J; Bennett L; Kostenko M; Landau M; Keidar S; Levy Y; Khemlin A; Radan A; Levy AP
Arterioscler Thromb Vasc Biol; 2008 Feb; 28(2):341-7. PubMed ID: 18032779
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus.
Nakhoul FM; Miller-Lotan R; Awad H; Asleh R; Jad K; Nakhoul N; Asaf R; Abu-Saleh N; Levy AP
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F830-8. PubMed ID: 19176700
[TBL] [Abstract][Full Text] [Related]
6. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype.
Asleh R; Blum S; Kalet-Litman S; Alshiek J; Miller-Lotan R; Asaf R; Rock W; Aviram M; Milman U; Shapira C; Abassi Z; Levy AP
Diabetes; 2008 Oct; 57(10):2794-800. PubMed ID: 18599520
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic interaction between the Haptoglobin genotype and vitamin E on atherosclerotic plaque progression and stability.
Veiner HL; Gorbatov R; Vardi M; Doros G; Miller-Lotan R; Zohar Y; Sabo E; Asleh R; Levy NS; Goldfarb LJ; Berk TA; Haas T; Shalom H; Suss-Toby E; Kam A; Kaplan M; Tamir R; Ziskind A; Levy AP
Atherosclerosis; 2015 Mar; 239(1):232-9. PubMed ID: 25618031
[TBL] [Abstract][Full Text] [Related]
8. The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus.
Dalan R; Liuh Ling G
Eur J Prev Cardiol; 2018 Sep; 25(14):1502-1519. PubMed ID: 29799294
[TBL] [Abstract][Full Text] [Related]
9. Is it time to screen for the haptoglobin genotype to assess the cardiovascular risk profile and vitamin E therapy responsiveness in patients with diabetes?
Vardi M; Levy AP
Curr Diab Rep; 2012 Jun; 12(3):274-9. PubMed ID: 22427005
[TBL] [Abstract][Full Text] [Related]
10. Impact of Vitamin E supplementation on vascular function in haptoglobin genotype stratified diabetes patients (EVAS Trial): a randomised controlled trial.
Dalan R; Goh LL; Lim CJ; Seneviratna A; Liew H; Seow CJ; Xia L; Chew DEK; Leow MKS; Boehm BO
Nutr Diabetes; 2020 Apr; 10(1):13. PubMed ID: 32341356
[TBL] [Abstract][Full Text] [Related]
11. Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype.
Asleh R; Levy AP
Antioxid Redox Signal; 2010 Feb; 12(2):209-17. PubMed ID: 19769483
[TBL] [Abstract][Full Text] [Related]
12. Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial.
Costacou T; Levy AP; Miller RG; Snell-Bergeon J; Asleh R; Farbstein D; Fickley CE; Pambianco G; de la Vega R; Evans RW; Orchard TJ
Acta Diabetol; 2016 Apr; 53(2):243-50. PubMed ID: 26002590
[TBL] [Abstract][Full Text] [Related]
13. Changing the face of diabetic care with haptoglobin genotype selection and vitamin e.
Levy NS; Levy AP
Rambam Maimonides Med J; 2011 Apr; 2(2):e0047. PubMed ID: 23908805
[TBL] [Abstract][Full Text] [Related]
14. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
15. Interaction Between the Haptoglobin Genotype and Vitamin E on Cardiovascular Disease in Diabetes.
Hochberg I; Berinstein EM; Milman U; Shapira C; Levy AP
Curr Diab Rep; 2017 Jun; 17(6):42. PubMed ID: 28451949
[TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of haptoglobin genotype as a risk of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Ateia AM; Elbassiouny A; El-Nabi SH; Fahmy NA; Ibrahim MH; El-Garawani I; Geba KM; Khalaf M
Clin Neurol Neurosurg; 2020 Dec; 199():106296. PubMed ID: 33069930
[TBL] [Abstract][Full Text] [Related]
18. Haptoglobin Genotype Is a Determinant of Hemoglobin Adducts and Vitamin E Content in HDL.
Goldenstein H; Levy NS; Ward J; Costacou T; Levy AP
J Diabetes Res; 2018; 2018():6125420. PubMed ID: 29888289
[TBL] [Abstract][Full Text] [Related]
19. Vitamin E Intake Is Associated with Lower Brain Volume in Haptoglobin 1-1 Elderly with Type 2 Diabetes.
Livny A; Schnaider Beeri M; Heymann A; Moshier E; Berman Y; Mamistalov M; Shahar DR; Tsarfaty G; Leroith D; Preiss R; Soleimani L; Silverman JM; Bendlin BB; Levy A; Ravona-Springer R
J Alzheimers Dis; 2020; 74(2):649-658. PubMed ID: 32065799
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
